The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Xtandi Significantly Prolongs PFS in PII Study in Europe, US: Astellas
January 27, 2015
- Senshio Approved in Europe for Treatment of Symptomatic Vulvar, Vaginal Atrophy: Shionogi
January 26, 2015
- Takara Bio to Initiate Clinical Trial for Anticancer Agent HF10 in Japan
January 26, 2015
- US FDA Advisory Committee Recommends Approval of Astellas’s Azole Antifungal Agent
January 26, 2015
- Nihon Chouzai Confident of Continuing Early Price Settlements
January 23, 2015
- Open Tenders Good Example of Early Price Settlements: Qol Exec
January 22, 2015
- Lifestyle Disease-Related Medical Spending Must Be Pruned: Nobelpharma Pres.
January 22, 2015
- Medical System Network President Calls for Scrapping Fee Cut Rule
January 21, 2015
- Sakura Finetek Japan to Participate in Cervical Cancer Screening Project in Kazakhstan
January 21, 2015
- Meiji Seika Pharma Licenses Darinaparsin from Solasia Pharma in Japan
January 20, 2015
- Sanofi Launches Allegra Dry Syrup for Pediatric Patients Aged 6 Months and Older
January 20, 2015
- Pharma Bigwigs Stress Importance of Early Patent Strategies
January 19, 2015
- Foreign-Affiliated Pharmas Looking to Make “Sure Investments” to Avoid Risk of Discontinued Development: PhRMA Official
January 19, 2015
- Mr Plata Named as AbbVie G.K.’s New President
January 19, 2015
- Belsomra Most Heavily Pitched Drug in November: Anterio Ranking
January 16, 2015
- Toyama Chemical Commences PII Study for Solithromycin in Japan
January 16, 2015
- Sumitomo Dainippon Files Latuda Patent Infringement Lawsuits in US against 3 Pharmas
January 16, 2015
- Otsuka Completes Acquisition of Avanir for US$3.56 Billion
January 15, 2015
- Lantus Biosimilar Approved: Eli Lilly Japan, NBI
January 15, 2015
- Takeda to Roll Out Colcrys AG in US
January 14, 2015
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…